null

Shop by Category

c-Met Kinase Inhibitors

c-Met (MET or mesenchymal-epithelial transition factor) is a prototype member of a subfamily of heterodimeric receptor tyrosine kinases (RTKs) and is the receptor for hepatocyte growth factor (HGF). MET can be activated through ligand-dependent or ligand-independent mechanisms. Binding of HGF to the MET extracellular domain results in receptor multimerization, phosphorylation, and activation of MET-dependent signal transduction inside the cell. Activation of the MET receptor leads to the activation of downstream signals, including the mitogen-activated protein kinase (ERK/ MAPK) and phosphatidylinositol 3-kinase (PI3K/AKT) pathways, STAT3, and RAS. Dysregulated HGF/c-Met signaling is a driving factor for several malignancies and promotes tumor growth, invasion, dissemination and angiogenesis. Dysregulated HGF/c-Met signaling has also been associated with poor clinical outcomes and resistance acquisition to some approved targeted therapies. Thus, c-Met kinase has emerged as a promising target for cancer drug development. Different therapeutic approaches targeting the HGF/c-Met signaling pathway are under development for targeted cancer therapy, among which small molecule inhibitors of c-Met kinase constitute the largest effort within the pharmaceutical industry. BioVision is proud to offer several structurally diverse small molecule c-Met kinase inhibitors for research.

Cat Product
26-9563 Altiratinib 
26-2553 AMG-208 
26-B3317 AMG-337 
26-2455 BMS-777607 
26-1935 Carbozantinib 
26-1934 Crizotinib 
26-B2628 EZSolution™ PF-04217903 
26-9476 Foretinib 
26-B2561 Glumetinib 
26-2655 Golvatinib 
26-B2063 JNJ-38877605 
26-B3359 MK-2461 
26-B2062 PF-04217903 
26-B2057 PHA-665752 
26-B2510 SAR-125844 
26-1938 SU 11274 
26-B1546 Tivantinib 

Biovision Complete Product Catalog

  

  • AMG-337

    Biovision | AMG-337 | B3317

    AMG-337 is a potent and selective inhibitor of c-Met kinase activity (IC50 = 1 nM) and adaptor protein Gab-1 phosphorylation, that subsequently blocks downstream PI3K and MAPK pathways. It has been shown to inhibit hepatocyte growth factor-mediated c-Met...

    $206.00 - $639.00
    Choose Options
  • Glumetinib

    Biovision | Glumetinib | B2561

    Glumetinib (SCC-244) is a potent and highly selective inhibitor of c-Met kinase (IC₅₀ = 0.42 nM). Glumetinib displays subnanomolar potency against c-Met kinase activity and high selectivity versus 312 other tested protein kinases.Glumetinib (SCC-244) is...

    $217.00 - $685.00
    Choose Options
  • SAR-125844

    Biovision | SAR-125844 | B2510

    SAR-125844 is a potent, selective, reversible and ATP-competitive c-MET inhibitor, with an IC₅₀ of 4.2 nM. Displays inhibition of MET autophosphorylation in cell-based assays. Upon intravenous administration, SAR-125844 binds to c-Met, thereby disrupting...

    $147.00 - $381.00
    Choose Options
  • SU 11274

    Biovision | SU 11274 | 1938

    A specific, ATP-competitive small molecule inhibitor of the catalytic activity of Met. Displays selectivity for Met enzyme versus a panel of other tyrosine kinases with the following IC₅₀ values: Met = 0.02 μM, Flk = 1.3 μM, EGFR = >100 μM, PDGFßR = >20...

    $229.00 - $721.00
    Choose Options
  • Carbozantinib

    Biovision | Carbozantinib | 1935

    Cell-permeable. A potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects.Carbozantinib is a potent inhibitor of MET, vascular endothelial growth factor...

    $212.00 - $650.00
    Choose Options
  • BMS-777607

    Biovision | BMS-777607 | 2455

    A potent, selective and ATP-competitive Met kinase superfamily inhibitor (IC₅₀ = 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM for c-Met, Axl, RON, and Tyro-3, respectively). it was >40-fold selective for Met kinase family targets versus Lck, VEGFR-2, and TrkA/B and...

    $206.00 - $615.00
    Choose Options
  • Altiratinib

    Biovision | Altiratinib | 9563

    Altiratinib is a selective and highly potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases with potential anticancer activity. It effectively reduces tumor burden in vivo and blocks c-MET pTyr(1349)-mediated signaling, cell growth and migration as...

    $206.00 - $639.00
    Choose Options
  • Crizotinib

    Biovision | Crizotinib | 1934

    A specific, ATP-competitive, small-molecule inhibitor of the receptor tyrosine kinases (RTKs) c-Met and anaplastic lymphoma kinase (ALK). Iinhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. Inhibits the growth and survival of...

    $212.00 - $650.00
    Choose Options
  • Tivantinib

    Biovision | Tivantinib | B1546

    Tivantinib (ARQ-197) is a potent, cell-permeable inhibitor of c-Met with potential antineoplastic activity. Tivantinib binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing...

    $159.00 - $451.00
    Choose Options
  • JNJ-38877605

    Biovision | JNJ-38877605 | B2063

    JNJ-38877605 is a potent c-MET tyrosine kinase inhibitor with potential anti-neoplastic activity. It is potent (IC₅₀ values of 4 nM and 50 nM for c-MET enzyme and Phospho-MET respectively). Displays selectivity over 229 other kinases tested.JNJ-38877605...

    $253.00 - $820.00
    Choose Options
  • Golvatinib

    Biovision | Golvatinib | 2655

    Golvatinib ( E7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase...

    $229.00 - $703.00
    Choose Options
  • AMG-208

    Biovision | AMG-208 | 2553

    AMG-708 is a selective small-molecule inhibitor (IC₅₀ = 9.3 nM) of the proto-oncogene c-Met with potential antineoplastic activity. AMG 208 inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity,...

    $253.00 - $820.00
    Choose Options
  • PF-04217903

    Biovision | PF-04217903 | B2062

    PF-04217903 is a novel ATP-competitive small-molecule inhibitor of c-Met kinase. PF-04217903 displays more than 1,000-fold selectivity for c-Met compared with more than 150 kinases. PF-04217903 inhibits tumor cell proliferation, survival,...

    $194.00 - $592.00
    Choose Options
  • PHA-665752

    Biovision | PHA-665752 | B2057

    PHA-665752 is a potent, selective and ATP-competitive inhibitor of MET kinase (IC₅₀ values are 9, 68, 200, 1400, 3000, 3800 and 6000 nM for MET, Ron, Flk-1, c-abl, FGFR1, EGFR and c-src respectively and > 10000 nM for IGF-IR, PDGFR, AURORA2, PKA, PKBα,...

    $217.00 - $685.00
    Choose Options
  • Foretinib

    Biovision | Foretinib | 9476

    Foretinib is an ATP-competitive multi-kinase inhibitor that suppresses the activity of hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor-2 (VEGFR-2). In addition, Foretinib suppresses angiogenesis and...

    $171.00 - $498.00
    Choose Options